Shanghai Changzheng Hospital

CARsgen's Allogeneic BCMA CAR-T Shows Promising Safety and Efficacy in Relapsed/Refractory Multiple Myeloma

11 days ago

• CARsgen's allogeneic BCMA-targeted CAR-T therapy CT0596 demonstrated a favorable safety profile with no dose-limiting toxicities or severe adverse events in relapsed/refractory multiple myeloma patients. • In preliminary efficacy data, 60% of evaluable patients achieved complete response, and 80% reached minimal residual disease negativity, with sustained responses observed through four months of follow-up. • Developed using CARsgen's proprietary THANK-u Plus™ platform, CT0596 shows potential for treating multiple myeloma and other plasma cell malignancies, with an IND application planned for late 2025.

Daratumumab Plus VRd Improves Outcomes in Transplant-Ineligible Multiple Myeloma Patients

6 months ago

• The phase 3 CEPHEUS trial demonstrated that adding daratumumab to VRd significantly improved outcomes for transplant-ineligible newly diagnosed multiple myeloma patients. • The quadruplet regimen achieved a 60.9% minimal residual disease (MRD) negativity rate compared to 39.4% with VRd alone, demonstrating a significant increase in treatment depth. • Progression-free survival was also significantly improved with the daratumumab regimen, showing a 43% reduction in the risk of disease progression or death. • These results suggest that daratumumab plus VRd could become a new standard of care for transplant-ineligible multiple myeloma patients, offering improved disease control.